The Device from Stuttering was Tested in Man
OREANDA-NEWS. Researchers from the National institutes of health turned off in mice the gene GNPTAB, a breakdown in which the people associated with stuttering, and to determine which cells in which part of the brain suffer most.
Scientists from the University of California riverside presented the results of the first clinical studies testing the drug in ecopipam (Ecopipam) among patients with different stuttering severity. In this stage of the research, according to Science Daily, the efficacy and safety of therapy was evaluated in nine men.
Positive results included increased speed of speech, more rapid completion of the reading and reducing the length of stuttering events. Ecopipam was well tolerated by study participants identified no serious side effects. According to lead author of the experiment Gerald Maguire, based on positive results, the drug will be tested in a larger scale early next year on the efficacy and safety in the United States.